Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Oversight May Be Ongoing Theme After Erbitux Hearing

Executive Summary

The "lack of discipline" among clinical trial investigators involved in colorectal cancer studies of ImClone/Bristol's Erbitux may suggest a need for congressional action, Rep. Ernie Fletcher (R-Ky.) said

You may also be interested in...



Erbitux Hearing Suggests Need To Revisit Fast Track Process – Rep. Burr

The Erbitux development problems suggest that the Fast Track process may not be working as well as expected, Rep. Richard Burr (R-N.C.) said during a June 13 Energy & Commerce/Oversight Subcommittee hearing on the ImClone/Bristol oncologic agent

Erbitux Hearing Suggests Need To Revisit Fast Track Process – Rep. Burr

The Erbitux development problems suggest that the Fast Track process may not be working as well as expected, Rep. Richard Burr (R-N.C.) said during a June 13 Energy & Commerce/Oversight Subcommittee hearing on the ImClone/Bristol oncologic agent

Bristol/ImClone Erbitux BLA Resubmission Expected During First Quarter

ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment

Related Content

UsernamePublicRestriction

Register

PS040040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel